Published in Clinical Trials Week, January 25th, 2010
The study, published online in Drug Metabolism and Disposition - one of the leading journals in the field of drug metabolism and pharmacokinetics - examined AstraZeneca's ximelagatran and its active metabolite, melagatran, both of which are actively secreted into bile. Previous clinical studies illustrated that when ximelagatran was co-administered with erythromycin, plasma levels of ximelagatran and melagatran were elevated, suggesting a drug-drug interaction. By using the CellPort...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.